

Invent Medic applies for patent and initiates testing of its innovative menstrual cup

Invent Medic announces that it has filed a first patent application to protect the unique features of its innovative menstrual cup that is being developed with a first launch planned for the second half of 2021. Furthermore, it is announced that the testing of two product prototypes will be initiated today with a total of 60 women in this first part of the testing program.

The patent application filed for the menstrual cup is a so-called priority application, that has been filed in Sweden with the option to be extended to an international application within a year. This means that it will form the basis of an international patent program for the menstrual cup, covering all of Invent Medic's important regional markets including Europe and the United States.

The first part of the testing program for the menstrual cup that is initiated today will utilise a testing panel with a total of 60 women. The participants have been divided into three groups: women who are experienced users of menstrual cup products, women who have tried menstrual cup products but see themselves as discontented users, and women who have not used menstrual cup products previously. The results from the testing program will contribute to the company's final adjustments towards a final menstrual cup product. Initial launch in Sweden is a planned for the second half of 2021.

"It is inspiring to be able to present this progress in the development of our innovative menstrual cup. I am happy that almost finalised versions of the Efemia menstrual cup will now be used, and that we will receive valuable feedback so that we can finalise it in the best way possible," says Invent Medic's CEO Karin Bryder.

For more information please contact

Karin Bryder, CEO

Phone: +46 (0)723811710

E-mail: info@inventmedic.com

About Invent Medic

Invent Medic Sweden AB (Invent Medic) is a Swedish company developing innovative products with the aim to improve women's health and quality of life. The company's products are to be safe, effective and easy to use. Invent Medic's first product, Efemia, is a CE-certified and patented medical technology product used to reduce stress urinary incontinence (SUI) that was shown to reduce urine leakage with 77 percent during usage in a clinical study. The product is based on the same scientific principle as the TVT method, the premier surgical treatment for SUI. Invent Medic's share is listed on the Spotlight Stock Market with the ticker symbol IMS, and the share's ISIN code is SE0007603402. More information can be found at www.inventmedic.com and www.spotlightstockmarket.com.